Innovation

The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.

Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.

From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more.

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.

Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world.

What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

A Johnson & Johnson scientist explains how the new Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.